Zobrazeno 1 - 10
of 47
pro vyhledávání: '"Kenneth A, Lichtenstein"'
Autor:
Frank J. Palella, Angela M. Thompson-Paul, Fleetwood Loustalot, Cathleen Gillespie, Deesha Patel, Kate Buchacz, Pragna Patel, Nabil Rayeed, Matthew D. Ritchey, Quanhe Yang, Kenneth A. Lichtenstein
Publikováno v:
AIDS
OBJECTIVE: Cardiovascular disease (CVD) is a common cause of morbidity and mortality among persons living with HIV (PLWH). We used individual cardiovascular risk factor profiles to estimate heart age for PLWH in medical care in the United States. DES
Autor:
Kathryn Anastos, Kate Buchacz, Timothy R. Sterling, Vincent Lo Re, M. John Gill, Frank J. Palella, Amy C. Justice, Anita Rachlis, Fidel A Desir, Lisa P. Jacobson, Jennifer E. Thorne, Cynthia M. Boyd, Stephen J. Gange, Cherise Wong, Angel M. Mayor, Heidi M. Crane, Michael A. Horberg, James H. Willig, Charles S. Rabkin, Kenneth A. Lichtenstein, Keri N. Althoff, Mari M. Kitahata, Marina B. Klein, Michael J. Silverberg, Robert Dubrow, Chad J. Achenbach, Kelly A. Gebo, Richard D. Moore, Daniel B. Klein, William C. Mathews, Yuezhou Jing, Gregory M. Lucas, Joseph J. Eron, Pragna Patel, Sonia Napravnik, Gregory D. Kirk
Publikováno v:
The lancet. HIV, vol 6, iss 2
Background: Adults with HIV have an increased burden of non-AIDS-defining cancers, myocardial infarction, end-stage liver disease, and end-stage renal disease. The objective of this study was to estimate the population attributable fractions (PAFs) o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af6b3d4c24384f4d4dd1d2fb4cc4ad1c
https://escholarship.org/uc/item/7r90z7hs
https://escholarship.org/uc/item/7r90z7hs
Autor:
Angela M. Thompson-Paul, John T. Brooks, Fleetwood Loustalot, Carl Armon, Jacek Skarbinski, Kenneth A. Lichtenstein, Frank J. Palella, Joan S. Chmiel, Rachel Hart, Stanley C. Wei, Kate Buchacz
Publikováno v:
Clinical Infectious Diseases. 63:1508-1516
BACKGROUND Cardiovascular disease (CVD) risk prediction tools are often applied to populations beyond those in which they were designed when validated tools for specific subpopulations are unavailable. METHODS Using data from 2283 human immunodeficie
Autor:
Nur F. Önen, Pragna Patel, Kenneth A. Lichtenstein, Edgar T. Overton, Tim Bush, Erna M. Kojic, Kristin Mondy, Gerome Escota, Keith Henry, Kathy Wood, John Hammer, John T. Brooks, Lois Conley
Publikováno v:
AIDS Research and Human Retroviruses. 32:59-67
HIV-infected persons are living longer on combination antiretroviral therapy (cART) but experiencing more comorbidities including low bone mineral density (BMD). Using data from the Study to Understand the Natural History of HIV and AIDS in the Era o
Autor:
Bonnie Dean, Frank J. Palella, John Hammer, Doug Ward, Rachel Hart, John T. Brooks, Benjamin Young, Kathleen C. Wood, Marcus D. Durham, Jerian Denise Dixon-Evans, Dania Beadle, Dana Franklin, Bienvenido G. Yangco, Richard M. Novak, Kate Buchacz, Jane Esteves, Conor Daniel Flaherty, Ellen Tedaldi, Jack Fuhrer, Cheryl Stewart, Faye Ruley, Ramona A. Christian, Thilakavathy Subramanian, Mia Scott, Kenneth S. Greenberg, Princess Graham, Darlene Hankerson, Linda Ording-Bauer, Kalliope Chagaris, Rita Kelly, Kenneth A. Lichtenstein, Rosa Franklin, Andrea Wendrow, Carl Armon, Renata Smith, Barbara Widick, Joan S. Chmiel, Saira Jahangir, Harlen Hays
Publikováno v:
Journal of Antimicrobial Chemotherapy. 70:2337-2346
BackgroundMonitoring antiretroviral drug resistance can inform treatment recommendations; however, there are few such data from US patients before they initiate ART.MethodsWe analysed data from HIV Outpatient Study (HOPS) participants from nine US HI
Autor:
Cathleen C Gillespie, Kenneth A. Lichtenstein, Angela M. Thompson-Paul, Kate Buchacz, Fleetwood Loustalot, Rachel Hart, Frank J. Palella, Nabil Rayeed, Matthew D. Ritchey, Quanhe Yang
Publikováno v:
Circulation. 135
Cardiovascular disease (CVD) is an important cause of morbidity and mortality among HIV-infected adults. Calculating an individual’s excess heart age, or the difference between their chronological age and predicted heart age, can be useful in descr
Autor:
Howard N. Hodis, John T. Brooks, Kenneth A. Lichtenstein, Matthew J. Budoff, Nur F. Önen, Pragna Patel, Eleanor Wilson, Jason V. Baker, Erna M. Kojic, Katherine Huppler Hullsiek, Amrit Singh, Keith Henry, Irini Sereti
Publikováno v:
AIDS (London, England), vol 28, iss 6
Background: Identifying immunologic mechanisms that contribute to premature cardiovascular disease (CVD) among HIV-positive patients will inform prevention strategies. Methods: Coronary artery calcium (CAC) progression was studied in an HIV cohort. I
Autor:
Keith Henry, Kenneth A. Lichtenstein, Lauren Shaw, Timothy J. Bush, John T. Brooks, Joan S. Chmiel, E. Turner Overton, R. Debes, Claudia Vellozzi, Frank J. Palella, Kate Buchacz, Pragna Patel, Charles C. J. Carpenter, Rose K. Baker, Kenneth H. Mayer, Ellen Tedaldi
Publikováno v:
Antiviral Therapy. 18:65-75
Background Certain sociodemographic subgroups of HIV-infected patients may experience more chronic disease than others due to behavioural risk factors, advanced HIV disease or complications from extended use of combination antiretroviral therapy (cAR
Autor:
Sandra Friborg, Martin S. Rhee, Gordon Crofoot, Christopher Lucasti, Eric S. Daar, Daniel Coulston, Craig Dietz, Anthony LaMarca, Kenneth A. Lichtenstein, Peter Shalit, Mingjin Yan, Joel E. Gallant
Publikováno v:
Open Forum Infectious Diseases. 3
Autor:
Devi SenGupta, Frank A. Post, Michael E. Abram, Mark Bloch, Samir K. Gupta, Gordon Crofoot, Joseph M. Custodio, Anchalee Avihingsanon, Scott McCallister, Kenneth A. Lichtenstein, Moti Ramgopal, Xuelian Wei, Joseph Gathe, Ploenchan Chetchotisakd, Anton Pozniak, Jose R. Arribas, Paul M. Benson, Marshall W. Fordyce, Andrew K. Cheng
Publikováno v:
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Journal of Acquired Immune Deficiency Syndromes (1999)
Consejería de Sanidad de la Comunidad de Madrid
Journal of Acquired Immune Deficiency Syndromes (1999)
Supplemental Digital Content is Available in the Text.
Background: Tenofovir alafenamide (TAF) is a novel tenofovir prodrug with improved renal and bone safety compared with TDF-containing regimens. We report the 48 week safety and efficacy of a
Background: Tenofovir alafenamide (TAF) is a novel tenofovir prodrug with improved renal and bone safety compared with TDF-containing regimens. We report the 48 week safety and efficacy of a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9eaaa052598d884fc52675c587855c38
https://hdl.handle.net/20.500.12530/28249
https://hdl.handle.net/20.500.12530/28249